<DOC>
	<DOCNO>NCT01096368</DOCNO>
	<brief_summary>This randomized phase III trial study maintenance chemotherapy see well work compare observation follow induction chemotherapy radiation therapy treat young patient newly diagnose ependymoma . Drugs use chemotherapy , vincristine sulfate , carboplatin , cyclophosphamide , etoposide , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Radiation therapy use high-energy x-ray kill tumor cell . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Giving chemotherapy radiation therapy may kill tumor cell allow doctor save part body cancer start .</brief_summary>
	<brief_title>Maintenance Chemotherapy Observation Following Induction Chemotherapy Radiation Therapy Treating Younger Patients With Newly Diagnosed Ependymoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine event-free survival ( EFS ) overall survival ( OS ) child completely resect ependymoma treat maintenance chemotherapy comprise vincristine sulfate , cisplatin , etoposide , cyclophosphamide ( VCEC ) versus observation follow post-operative conformal radiotherapy ( cRT ) . SECONDARY OBJECTIVES : I . To estimate EFS OS child incompletely resect ependymoma unable achieve complete response ( CR ) post-operative induction chemotherapy second surgery non-randomly assign cRT follow VCEC . II . To evaluate EFS OS child supratentorial classic ependymoma achieve complete resection first second resection child achieve CR short-course induction chemotherapy follow first surgery . III . To determine neurologic , neuropsychological , endocrine long-term sequela surgery , cRT , VCEC compare patient treat COG-ACNS0121 . IV . To determine biologic prognostic factor childhood ependymoma utilizing genomic profile via comparative genomic hybridization single-nucleotide polymorphism array , microarray gene expression profile analysis initial tumor sample correlate clinical outcome . V. To evaluate prognostic immune-function gene expression ependymomas . VI . To build upon data derive COG-ACNS0121 develop genotypically base classification signature correlate WHO grade , location , extent resection , treatment , EFS , OS . VII . To evaluate telomere maintenance prognostic marker . OUTLINE : This multicenter study . Patients stratify accord extent resection initial surgery ( total v near total resection ) , tumor histology , tumor location ( infratentorial primary tumor v supratentorial anaplastic tumor ) . Patients randomize 1 2 treatment arm . Patients supratentorial classic tumor assign arm II . All patient receive induction chemotherapy comprise vincristine sulfate IV day 1 8 , carboplatin IV 15-60 minute day 1 , cyclophosphamide IV 30-60 minute day 1-2 . Patients also receive etoposide IV 60-120 minute day 1-3 course 2 . Treatment repeat every 3 week 2 course absence disease progression unacceptable toxicity . Patients achieve stable disease , partial response , locally progressive disease deem potentially resectable undergo surgery within 15 day completion induction chemotherapy . ARM I : Patients undergo conformal radiotherapy 6-7 week . Patients receive vincristine sulfate IV day 1 , 8 , 15 ( course 1-3 ) ; etoposide IV 1-2 hour day 1-3 ; cisplatin IV 1-8 hour day 1 ; cyclophosphamide IV 30-60 minute day 1-2 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . ARM II : Patients undergo conformal radiotherapy 6-7 week . Some patient undergo blood tissue sample collection treatment surgery gene expression microarray , genomic hybridization array , correlative study . After completion study therapy , patient follow every 4 month 5 year .</detailed_description>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histologically confirm intracranial ependymoma meeting follow criterion : Newly diagnose disease Classic ependymoma ( WHO II ) anaplastic ependymoma ( WHO III ) , include follow subtypes : Clear cell Papillary Cellular Combination No diagnosis spinal cord ependymoma , myxopapillary ependymoma , subependymoma , ependymoblastoma , mixed glioma Has undergone surgical resection primary tumor More 1 attempted resection allow No metastatic disease MRI cerebrospinal fluid ( CSF ) cytology CSR cytology ventriculostomy permanent VP shunt reveals presence tumor cell indicative metastatic disease No evidence noncontiguous spread beyond primary site determine pre postoperative MRI brain , pre postoperative MRI spine , postoperative CSF cytology obtain lumbar CSF space Lumbar CSF examination may waive deem medically contraindicated ECOG performance status ( PS ) 02 Karnofsky PS patient &gt; 16 year age Lansky PS patient ≤ 16 year age ANC ≥ 1,000/μL Platelet count ≥ 100,000/μL ( transfusion independent ) Creatinine clearance radioisotope GFR ≥ 70 mL/min OR serum creatinine base age/gender follow : 0.4 mg/dL ( 1 month &lt; 6 month age ) 0.5 mg/dL ( 6 month &lt; 1 year age ) 0.6 mg/dL ( 1 2 year age ) 0.8 mg/dL ( 2 &lt; 6 year age ) 1.0 mg/dL ( 6 10 year age ) 1.2 mg/dL ( 10 13 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( 13 &lt; 16 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( ≥ 16 year age ) Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ( ≤ 3 time ULN patient Gilbert syndrome hemolytic anemia ) AST ALT &lt; 3 time ULN Adequate cardiac function define 1 following : Shortening fraction ≥ 27 % ECHO Ejection fraction ≥ 50 % gate radionuclide study . Not pregnant nursing Patients agree stop nursing study allow Negative pregnancy test Fertile patient must use effective contraception No prior treatment ependymoma surgical intervention corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>